Abstracts tagged "DMARDs"

Abstract Number: 1242 • 2014 ACR/ARHP Annual Meeting
Switching Biologic Agents in Refractory Adult-Onset Still’s Disease: Efficacy and Safety in a Cohort of 20 Patients at a Single Referral Center
Giulio Cavalli¹, Stefano Franchini¹, Corrado Campochiaro¹, Elena Baldissera², Lorenzo Dagna³ and Maria Grazia Sabbadini³, ¹Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, ²Clinical immunopathology and advanced medical therapeutics, San Raffaele Scientific Institute, Milan, Italy, ³Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milano, Italy
Background/Purpose No data is available on the long-term clinical outcome of Adult-Onset Still's Disease (AOSD) patients treated with biological drugs, nor on the efficacy and…
Abstract Number: 2494 • 2014 ACR/ARHP Annual Meeting
Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare
Jonathan Kruger¹, Michael Morgan¹, Andreas Reimold², Ted R. Mikuls³, Gail Kerr⁴ and Grant W. Cannon⁵, ¹Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Rheumatology, Dallas VA and Univ of TX Southwestern Med Ct, Dallas, TX, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, Washington DC VA and Georgetown and Howard University, Washington, DC, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Few rheumatoid arthritis (RA) patients are managed successfully with a single disease modifying anti-rheumatic drug (DMARD). This investigation determined the prevalence and clinical…
Abstract Number: 944 • 2014 ACR/ARHP Annual Meeting
Predict the Chance of Remission for Your RA Patient in Real Life
Till Uhlig¹, Vibeke Norvang², Elisabeth Lie¹, Erik Rødevand³, Knut Mikkelsen⁴, Åse S. Lexberg⁵, Synøve Kalstad⁶ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ⁴Revmatismesykehuset, Lillehammer, Norway, ⁵Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁶Rheumatology, University Hospital of Northern Norway, Tromsø, Norway
Background/Purpose: Clinical remission (REM) is the treatment target in rheumatoid arthritis (RA), and there are several composite REM criteria available. Knowledge on how disease duration affects REM…
Abstract Number: 2419 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biologic Medications in Active Rheumatoid Arthritis: A Systematic Review
Lynden Roberts^1,2, Kathleen Tymms³, Julien de Jager⁴, Geoffrey Littlejohn⁵, Hedley Griffiths⁶, David Nicholls⁷, Paul Bird⁸, Jennifer Young⁹ and Jane Zochling¹⁰, ¹JCU Clinical School, Townsville, QLD, Australia, ²Monash Medical Centre, Clayton, VIC, Australia, ³Canberra Rheumatology, Canberra, ACT, Australia, ⁴Olser House, Southport, QLD, Australia, ⁵Rheumatology, Monash Medical Centre and Monash University, Clayton, VIC, Australia, ⁶Barwon Rheumatology Service, Geelong, VIC, Australia, ⁷Coast Joint Care, Maroochydore, QLD, Australia, ⁸Combined Rheumatology Practice, Sydney, NSW, Australia, ⁹4-10 Inman Road, Roche Products Pty Limited, Sydney, NSW, Australia, ¹⁰Department of Rheumatology, Menzies Research Institute Tasmania, Hobart, TAS, Australia
Background/Purpose: In the last decade, biologic medications have transformed the management of RA. The effectiveness of these medications has been reported in numerous randomized controlled…
Abstract Number: 848 • 2014 ACR/ARHP Annual Meeting
Malignant Progression of Precancerous Lesions of the Uterine Cervix Following DMARD Therapy in Female Arthritis Patients
René Cordtz¹, Lene Mellemkjær², Bente Glintborg¹, Merete Lund Hetland³ and Lene Dreyer¹, ¹Department of Rheumatology, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Virus, Lifestyle and Genes, The Danish Cancer Society, Copenhagen, Denmark, ³DANBIO Registry and Department of Rheumatology., Copenhagen University Hospital Glostrup. On behalf of all departments of Rheumatology in Denmark., Glostrup, Denmark
Background/Purpose Recent studies have found that a high proportion of female rheumatoid arthritis (RA) patients are chronic carriers of high-risk HPV-strains and that these patients…
Abstract Number: 2388 • 2014 ACR/ARHP Annual Meeting
DMARD Use after an Initial Acute MI Is Associated with Reduced Risk of a Recurrent Event and Mortality
Jie Zhang¹, Fenglong Xie², Lang Chen³, Huifeng Yun⁴, Paul M. Muntner⁵, Emily Levitan⁵, Monica Safford⁶, Kenneth G. Saag⁷, Jasvinder A. Singh⁶ and Jeffrey R. Curtis⁶, ¹Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Previous studies have suggested that disease modifying anti-rheumatic drugs (DMARDs) may reduce cardiovascular risk among patients with rheumatoid arthritis (RA). This analysis examined whether…
Abstract Number: 845 • 2014 ACR/ARHP Annual Meeting
The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication
Layla Saliba¹, Guillaume Moulis², Malak Aboutaam³, Grégory Pugnet², Vanessa Rousseau¹, Leila Chebane¹, Nadine Petitpain⁴, Bernadette Baldin⁵, Jean-Louis Montastruc¹ and Haleh Bagheri¹, ¹Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, Toulouse, France, ²Toulouse University Hospital, Department of Internal Medicine, University of Toulouse, INSERM UMR 1027, Toulouse, France, ³Reims University Hospital, Pharmacovigilance Regional Center, Reims, France, ⁴Nancy University Hospital, Pharmacovigilance Regional Center, Nancy, France, ⁵Nice University Hospital, Pharmacovigilance Regional Center, Nice, France
Background/Purpose: The risk of cancer with TNF-a inhibitor (TNFi) in patients concomitantly exposed to non-biological immunosuppressants (NBIS) is highly debated in RA, AS and psoriasis/PsA.…
Abstract Number: 2368 • 2014 ACR/ARHP Annual Meeting
Impact of Physicians’ Adherence to Treat-to-Target Strategy on Outcomes in Early Rheumatoid Arthritis
Laura Kuusalo¹, Kari Puolakka², Hannu Kautiainen³, Marjatta Leirisalo-Repo⁴ and Vappu Rantalaiho⁵, ¹Department of Internal Medicine, Division of Rheumatology, Turku University Hospital, Turku, Finland, ²Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ³Medcare Oy, Äänekoski, Finland, ⁴Department of Medicine, Division Of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁵Department of Internal Medicine, Centre for Rheumatic Diseases,, Tampere University Hospital, Tampere, Finland
Background/Purpose We have previously shown that in early rheumatoid arthritis (RA) remission targeted, intensive combination treatment, regardless of initial infliximab, results in remission in most…
Abstract Number: 480 • 2014 ACR/ARHP Annual Meeting
Serious Infection Risk By Treatments and Types in Patients with RA
Kaleb Michaud^1,2, Sofia Pedro¹, Andre Kalil³, Ted R. Mikuls⁴ and Frederick Wolfe¹, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Recent studies provide conflicting results on the impact of DMARDs on the risk of serious infections for patients with RA. We examined these infection…
Abstract Number: 2205 • 2014 ACR/ARHP Annual Meeting
Management of Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease
Dominick Sudano¹, Varun Bhalla², Neil M. Ampel^3,4 and Jeffrey R. Lisse⁵, ¹Rheumatology, University of Arizona, Tucson, AZ, ²University of Arizona, Tucson, AZ, ³Infectious Disease, University of Arizona, Tucson, AZ, ⁴Infectious Disease, Southern Arizona Veteran's Affairs Medical Center, Tucson, AZ, ⁵Department of Rheumatology, University of Arizona, Tucson, AZ
Background/Purpose: In the Southwestern United States, coccidioidomycosis (valley fever) is an endemic fungal infection which typically causes a self-limited pulmonary illness. Immunosuppressed patients, including those…
Abstract Number: 496 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Induction Therapy for Rheumatoid Arthritis with Simultaneous Administration of Methotrexate and Low-Dose Tacrolimus: A Retrospective Study
Takashi Nakanishi¹, Hideyuki Horikoshi¹, Reiko Takahashi¹, Kanami Tongu², Junko Nishioka², Fumihiko Kimura³, Yuichi Nishioka² and Kenji Itoh¹, ¹Division of Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan, ²Nishioka Clinic for Rheumatic Diseases and Allergic Diseases, Kofu, Japan, ³National Defense Medical College, Tokorozawa, Japan
Background/Purpose Additional administration of low-dose tacrolimus (LD-TAC) at 0.5–1.0 mg daily was reported to be quite effective for rheumatoid arthritis (RA) patients with inadequate response…
Abstract Number: 2646 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis Of Triple Therapy Versus Etanercept Plus Methotrexate In Early Aggressive Rheumatoid Arthritis: Analysis Based On The TEAR Trial
Hawre Jalal¹, Jeffrey R. Curtis², Stacey Cofield³, Larry W. Moreland⁴, James R. O'Dell⁵ and Kaleb Michaud⁶, ¹Health Polisy and Management, University of Minnesota, Minneapolis, MN, ²Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The long-term cost-effectiveness of triple therapy (methotrexate [MTX], sulfasalazine [SSZ], hydroxychloroquine [HCQ]) disease modifying anti-rheumatic drugs (DMARDs) compared to a combination of MTX and…
Abstract Number: 1040 • 2013 ACR/ARHP Annual Meeting
Use Of TNF Inhibitors Is Associated With a Reduced Risk Of Diabetes In RA Patients
Siri Lillegraven¹, Jeffrey D. Greenberg², George W. Reed³, Katherine C. Saunders³, Jeffrey R. Curtis⁴, Leslie R. Harrold⁵, Marc C. Hochberg⁶, Dimitrios A. Pappas⁷, Joel M. Kremer⁸ and Daniel H. Solomon⁹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²NYU Hospital for Joint Diseases, New York, NY, ³Corrona, LLC., Southborough, MA, ⁴Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁷Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ⁸Center for Rheumatology, Albany Medical College, Albany, NY, ⁹Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: Inflammation may contribute to diabetes risk, and some studies indicate that certain DMARDs might be associated with a reduced risk of diabetes. Most studies…
Abstract Number: L14 • 2013 ACR/ARHP Annual Meeting
For Remission Induction with Glucocorticoid Bridging, Methotrexate Monotherapy Is As Effective As a Combination with Other Dmards, with Fewer Reported Side Effects: 4 Month Primary Outcome of Carera, a Randomized Induction Strategy and Treat to Target Trial in Early RA
Diederik De Cock¹, Sabrina Meyfroidt¹, Johan Joly², Kristien Van der Elst^2,3, Rene Westhovens^4,5 and Patrick Verschueren^2,6, ¹Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, ²University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ³Skeletal Biology and Engineering Research Center, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium, ⁴University of Leuven, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration; Rheumatology, University Hospital Leuven, Leuven, Belgium, ⁵Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, KU Leuven, Leuven, Belgium, ⁶1Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium
Background/Purpose: Intensive combination therapy with glucocorticoids (GCs) is the most favorable treatment to benefit from the window of opportunity in early Rheumatoid Arthritis (eRA) but…
Abstract Number: 2483 • 2013 ACR/ARHP Annual Meeting
Periarticular Bone Gain In Early Psoriatic Arthritis But Not In Rheumatoid Arthritis Following Anti-Rheumatic Treatment As Measured By Digital X-Ray Radiogrammetry
Agnes Szentpetery¹, Muhammad Haroon², Phil Gallagher³, Eric J. Heffernan⁴ and Oliver FitzGerald², ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Radiology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Hand bone loss is an early feature in both RA and PsA, but there is less data available on periarticular bone gain, in particular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].